Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Discovery of Epidermal Growth Factor‐Like 7 as a Potential Non‐Invasive Biomarker for Fibrosis and Mortality Risk in MASLD. Local targets link to admitted publications; unresolved targets remain external evidence.
A Multisociety Delphi Consensus Statement on New Fatty Liver Disease Nomenclature
10.1097/hep.0000000000000520 · 2023 · External reference
Natural History and Progression of Metabolic Dysfunction‐Associated Steatotic Liver Disease
10.1016/s2468-1253(24)00193-6 · 2024 · External reference
Fibrosis Stage Is the Strongest Predictor for Disease‐Specific Mortality in NAFLD After up to 33 Years of Follow‐Up
10.1002/hep.27368 · 2015 · External reference
Liver Fibrosis, but no Other Histologic Features, Is Associated With Long‐Term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
10.1053/j.gastro.2015.04.043 · 2015 · External reference
Fibrosis Stage but Not NASH Predicts Mortality and Time to Development of Severe Liver Disease in Biopsy‐Proven NAFLD
10.1016/j.jhep.2017.07.027 · 2017 · External reference
Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta‐Analysis
10.1053/j.gastro.2020.01.043 · 2020 · External reference
Design and Validation of a Histological Scoring System for Nonalcoholic Fatty Liver Disease
10.1002/hep.20701 · 2005 · External reference
Limitations of Liver Biopsy and Non‐Invasive Diagnostic Tests for the Diagnosis of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
10.3748/wjg.v20.i2.475 · 2014 · External reference
Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease
10.1053/j.gastro.2005.03.084 · 2005 · External reference
Prognostic Accuracy of FIB‐4, NAFLD Fibrosis Score and APRI for NAFLD‐Related Events: A Systematic Review
10.1111/liv.14669 · 2021 · External reference
Comparison of ADAPT, FIB‐4 and APRI as Non‐Invasive Predictors of Liver Fibrosis and NASH Within the CENTAUR Screening Population
10.1016/j.jhep.2021.08.016 · 2021 · External reference
Steatotic Liver Disease
10.1016/s0140-6736(24)01811-7 · 2024 · External reference
FIB‐4: An Inexpensive and Accurate Marker of Fibrosis in HCV Infection. Comparison With Liver Biopsy and FibroTest
10.1002/hep.21669 · 2007 · External reference
Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease
10.1053/j.gastro.2021.07.049 · 2021 · External reference
AASLD Practice Guidance on the Clinical Assessment and Management of Nonalcoholic Fatty Liver Disease
10.1097/hep.0000000000000323 · 2023 · External reference
EASL–EASD–EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD)
10.1016/j.jhep.2024.04.031 · 2024 · External reference
American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co‐Sponsored by the American Association for the Study of Liver Diseases (AASLD)
10.1016/j.eprac.2022.03.010 · 2022 · External reference
Age as a Confounding Factor for the Accurate Non‐Invasive Diagnosis of Advanced NAFLD Fibrosis
10.1038/ajg.2016.453 · 2017 · External reference
Prognostic Value of Non‐Invasive Fibrosis and Steatosis Tools, Hepatic Venous Pressure Gradient (HVPG) and Histology in Nonalcoholic Steatohepatitis
10.1371/journal.pone.0128774 · 2015 · External reference
Fibrosis‐4 Index as an Independent Predictor of Mortality and Liver‐Related Outcomes in NAFLD
10.1002/hep4.1841 · 2022 · External reference
Simple Non‐Invasive Fibrosis Scoring Systems Can Reliably Exclude Advanced Fibrosis in Patients With Non‐Alcoholic Fatty Liver Disease
10.1136/gut.2010.216077 · 2010 · External reference
Natural History of Nonalcoholic Fatty Liver Disease: A Prospective Follow‐Up Study With Serial Biopsies
10.1002/hep4.1134 · 2018 · External reference
Long‐Term Follow‐Up of Patients With NAFLD and Elevated Liver Enzymes
10.1002/hep.21327 · 2006 · External reference
Homogeneous Antibody‐Based Proximity Extension Assays Provide Sensitive and Specific Detection of Low‐Abundant Proteins in Human Blood
10.1093/nar/gkr424 · 2011 · External reference
Homogenous 96‐Plex PEA Immunoassay Exhibiting High Sensitivity, Specificity, and Excellent Scalability
10.1371/journal.pone.0095192 · 2014 · External reference
Feature Selection With the Boruta Package
10.18637/jss.v036.i11 · 2010 · External reference
Consistent Feature Selection for Pattern Recognition in Polynomial Time
2007 · External reference
Unresolved reference
External reference
Building Predictive Models in R Using the Caret Package
10.18637/jss.v028.i05 · 2008 · External reference
ranger: A Fast Implementation of Random Forests for High Dimensional Data in C++ and R
10.18637/jss.v077.i01 · 2017 · External reference
MissForest—Non‐Parametric Missing Value Imputation for Mixed‐Type Data
10.1093/bioinformatics/btr597 · 2012 · External reference
The UK Biobank Resource With Deep Phenotyping and Genomic Data
10.1038/s41586-018-0579-z · 2018 · External reference
Plasma Proteomic Associations With Genetics and Health in the UK Biobank
10.1038/s41586-023-06592-6 · 2023 · External reference
Non‐Alcoholic Fatty Liver Disease and Vitamin D in the UK Biobank: A Two‐Sample Bidirectional Mendelian Randomisation Study
10.3390/nu15061442 · 2023 · External reference
Index for Rating Diagnostic Tests
10.1002/1097-0142(1950)3:1<32::aid-cncr2820030106>3.0.co;2-3 · 1950 · External reference
The Youden Index and the Optimal Cut‐Point Corrected for Measurement Error
10.1002/bimj.200410133 · 2005 · External reference
Youden Index and Optimal Cut‐Point Estimated From Observations Affected by a Lower Limit of Detection
10.1002/bimj.200710415 · 2008 · External reference
Non‐Invasive Biomarkers of Nonalcoholic Steatohepatitis: The FNIH NIMBLE Project
10.1038/s41591-021-01652-8 · 2022 · External reference
NAFLD and NASH Biomarker Qualification in the LITMUS Consortium—Lessons Learned
10.1016/j.jhep.2022.11.028 · 2023 · External reference
Machine Learning Approaches to Enhance Diagnosis and Staging of Patients With MASLD Using Routinely Available Clinical Information
10.1371/journal.pone.0299487 · 2024 · External reference
EGFL7: A Unique Angiogenic Signaling Factor in Vascular Development and Disease
10.1182/blood-2011-10-322446 · 2012 · External reference
Angiogenesis in the Progression From Liver Fibrosis to Cirrhosis and Hepatocelluar Carcinoma
10.1080/17474124.2021.1842732 · 2021 · External reference
Angiogenesis and Fibrogenesis in Chronic Liver Diseases
10.1016/j.jcmgh.2015.06.011 · 2015 · External reference
Crosstalk Between Angiogenesis, Cytokeratin‐18, and Insulin Resistance in the Progression of Non‐Alcoholic Steatohepatitis
10.3748/wjg.15.5193 · 2009 · External reference
Novel Role for Epidermal Growth Factor‐Like Domain 7 in Metastasis of Human Hepatocellular Carcinoma
10.1002/hep.23197 · 2009 · External reference
Maladaptive Regeneration—The Reawakening of Developmental Pathways in NASH and Fibrosis
10.1038/s41575-020-00365-6 · 2020 · External reference
